Protein disulfide isomerase (PDI) catalyzes the oxidation-reduction and isomerization of disulfide bonds. We have previously identified an important role for extracellular PDI during thrombus formation in vivo. Here, we show that endothelial cells are a critical cellular source of secreted PDI, important for fibrin generation and platelet accumulation in vivo. Functional PDI is rapidly secreted from human umbilical vein endothelial cells in culture upon activation with thrombin or following laser-induced stimulation. PDI is localized in different cellular compartments in activated and quiescent endothelial cells, and is redistributed to the plasma membrane following cell activation. In vivo studies using intravital microscopy show that PDI appears rapidly after laser-induced vessel wall injury, prior to the appearance of the platelet thrombus. If platelet thrombus formation is inhibited by the infusion of eptifibatide into the circulation, PDI is detected following vessel wall injury and fibrin deposition is normal. Treatment of mice with a function blocking PDI antibody completely inhibits fibrin generation in eptifibatidetreated mice. These results indicate that, although both platelets and endothelial cells secrete PDI following laser-induced injury, PDI from endothelial cells is required for fibrin generation in vivo.
Introduction
A considerable body of evidence implicates the oxidation state of labile disulfide bonds in critical hemostatic proteins in regulating the process of thrombus formation (1) . The oxidation state of these bonds is regulated by an enzyme(s) of the thiol isomerase family. Thiol isomerases, including protein disulfide isomerase (PDI), while containing endoplasmic reticulum retention signals are found extracellularly. Among the cells that secrete PDI and display the enzyme on their surface are platelets and endothelial cells (2, 3, 4, 5, 6, 7) . The importance of thiol-disulfide balance for platelet function has long been recognized. For example, reduced glutathione and cysteine inhibit platelet aggregation induced by several agonists while dithiothreitol and β-mercaptoethanol promote aggregation (4) . PDI likely plays an important role in maintaining this balance. The levels of both PDI and ERp5, another member of the protein disulfide isomerase family, on the platelet surface increase significantly upon agonist stimulation (4, 6) . PDI has been implicated in α IIb β 3 and α 2 β 1 activity (8, 9) and glycoprotein Ib-alpha expresses one or more free thiols on the activated platelet surface but not on resting platelets (4) . Inhibitory anti-PDI antibodies or bacitracin, a non-specific inhibitor of thiol isomerases, inhibit platelet activation in vitro, suggesting that α IIb β 3 -dependent platelet aggregation and secretion require thiol isomerases (10) . PDI may play a role in the deencryption of tissue factor (11, 12, 13) .
In contrast, there is less information to support potential roles of extracellular thiol isomerases in the function of endothelial cells. Endothelial cells in culture secrete PDI which then is bound to the cell surface (5) . A novel thiol isomerase that appears to be endothelial cellspecific, EndoPDI or ERp46, has been reported (14) . Recent evidence indicates that the protein disulfide isomerases, ERp46 and ERp57, are present in endothelial cell plasma membrane preparations (15) . Endothelial cells in culture secrete an activity that reduces the size of very large multimers of von Willebrand factor (vWF) (16) . This activity appears to be independent of For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the proteolysis of vWF by ADAMTS13 and is inhibited by thiol blocking reagents. The vWF reductant secreted from endothelial cells has been identified as thrombospondin-1 (17) . A functional role for extracellular thiol isomerases on endothelial cell activation has not been explored.
We and others have recently determined that PDI plays a significant role in thrombus formation in vivo (18, 38) . Using intravital fluorescence microscopy following laser-induced vessel wall injury in mouse cremaster muscle arterioles we determined that there is a timedependent increase in PDI at the site of thrombus formation following injury. Infusion of bacitracin or a blocking monoclonal antibody to PDI into the circulation inhibited both platelet thrombus formation and fibrin generation (18) . Although the presence of PDI in plasma has been controversial (19, 20) we do not detect significant amounts of PDI in human or mouse plasma (vide infra). Hence, the PDI that plays a role in thrombus formation is likely contributed by cells activated at the site of thrombus formation.
Fibrin deposition is normal in our laser thrombosis model in mice lacking the thrombin receptor PAR4 (21) . Although there is initial platelet accumulation following laser-induced arteriolar injury in these mice, platelet accumulation is minimal and the platelets in the juxtamural thrombus that forms in Par4 -/-mice are activated only after a long delay. These results suggest that platelets within the juxtamural thrombi cannot support fibrin generation (21) .
Inhibition of PDI eliminated fibrin accumulation in Par4 -/-mice, indicating that the enzyme plays a necessary role in thrombin generation in this model. Inhibition of PDI also eliminated the small juxtamural thrombus usually formed in Par4 -/-mice. Analysis of the kinetics of PDI expression after laser-induced vessel injury shows the appearance of PDI before platelet accumulation (18) . Thus there must be an alternative to the activated platelet as a source of PDI at the site of laser-induced vessel wall injury. Since endothelial cells lining the arteriolar wall are the direct target of the laser injury in this thrombosis model we have explored the role of endothelial PDI in For personal use only. on October 31, 2017. by guest www.bloodjournal.org From thrombus formation. Here we show that endothelial PDI is required for fibrin generation whereas platelet PDI contributes to the total amount of thrombus-associated PDI but is not required.
Materials and Methods
Animals. C57BL/6J WT mice were obtained from Jackson Laboratory (Bar Harbor, ME). The Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee approved all animal care and experimental procedures.
Antibodies and reagents. Rat anti-mouse CD41 antibody (clone MWReg30) and R300 platelet depleting antibodies against mouse GP1bα were purchased from Emfret (Germany). Fab fragments from the CD41 antibody were generated using the ImmunoPure Fab Preparation Kit washed with PBS, rinsed with serum-free Medium for 10 minutes, and incubated overnight in fresh serum-free medium. To induce regulated secretion of protein disulfide isomerase (acute release), these cells were incubated for the indicated times with: 1 NIH U/ml of human α -thrombin, 10 μM calcium ionophore A23187, 0.1 mM histamine or 100 ng/ml PMA. The medium was collected at specific time points. PDI in serum-free media from resting and activated HUVECs was detected by immunoblotting. The amount of PDI secreted from resting and activated cells was quantitated by comparison of the density units of known amounts of purified recombinant human PDI.
Protein disulfide isomerase activity. PDI activity was determined in the medium of thrombinactivated endothelial cells using the insulin transhydrogenase assay (39). Bovine insulin (1 mg/ml) in 250 μ l of 50 mM Tris-HCl buffer, pH 7.5, was incubated with 50 μ l of HUVEC medium in the presence or absence of the monoclonal RL90 antibody or an isotype-matched IgG2a control. The turbidometric assay of insulin disulfide reduction by PDI was initiated with 3 ml of 100 mM dithiothreitol and the reaction monitored at 650 nm over 60 minutes.
Intravital Microscopy. Intravital video microscopy of the cremaster muscle microcirculation was performed as previously described (28, 31). The intravital fluorescence microscopy system has previously been described in detail (32). Confocal intravital images were obtained using a Post-fixation, the cells were washed with 1X PBS and stained with anti-fibrin antibody (clone 59D8) or an isotype control antibody. For studies involving cellular localization of PDI, fixed cells were permeabilized with 1% Triton X-100 for 5 minutes and blocked with 5% normal goat serum. Specific antibodies to PDI (monoclonal RL90), von Willebrand factor (polyclonal anti vWF), or SERCA 2b (clone 2A7-A1)) were used. An idiotype-matched antibody was used as a control followed by appropriate Alexa 488 or Alexa 647-labeled secondary antibodies. For double labeling, the primary and secondary antibody cycle was repeated with a second set of antibodies. Images were captured using a Roper Coolsnap HQ camera. 
Results

Regulated secretion of PDI from endothelial cells
PDI is distributed in different cytosolic compartments in resting and active endothelial cells:
Since endothelial cells secrete PDI upon agonist stimulation, we performed density gradient centrifugation to determine the distribution of PDI in cellular fractions in resting and activated endothelial cells. SDS gel electrophoresis and Western blot analysis of density gradient fractions from lysates of resting endothelial cells showed that PDI was detected as a single, almost symmetrical peak, with a maximum at density 1.087 g/ml and a range of 1.06-1.12 g/ml ( Figure 2 A and B) . Both the peak of PDI activity, as measured by the insulin transhydrogenase assay, and the peak of PDI antigen were found at the same position in the gradient ( Figure 2B , fraction 9). The correlation between PDI activity and antigen in 14 fractions in two repeat experiments was >0.97. The peak density for the endoplasmic reticulum markerSERCA2b (22) was found at density 1.099 g/ml, and SERCA2b was distributed among fractions of density 1.059-1.121 g/ml. This distribution was very similar to that of PDI in the resting cells. Analysis of lysates from activated endothelial cells showed that PDI antigen and activity were present in fractions of broader density range from 1.045-1.12 g/ml. Alkaline phosphatase (AP), a marker for the plasma membrane, was detected around density 1.03-1.08 g/ml ( Figure 2C ), suggesting that PDI may be located on the plasma membrane of activated endothelial cells. PDI was not found in fractions containing the Weibel-Palade body marker, vWF, which was detected at densities between 1.11-1.17 g/ml.
PDI is localized to a distinct cytosolic compartment in HUVECs:
The rapid release of PDI from
HUVECs in response to thrombin, PMA and histamine suggests that PDI is stored in a distinct compartment for regulated secretion. However the results of cell fractionation experiments indicated that PDI is not stored in Weibel-Palade bodies, the most prominent storage granules of endothelial cells. We used confocal and electron microscopy to further establish the cellular location of PDI. As anticipated, PDI was partially co-localized with the endoplasmic reticulum resident protein SERCA2b in paraformaldehyde-fixed HUVECs ( Figure 3A ). Punctate PDI staining was also observed in the cytosol of HUVECs, but, as in the cell fractionation studies, the PDI-containing storage granules did not co-localize with vWF in Weibel-Palade bodies ( Figure 3B ). Distinct chemokine-containing granules have been described in endothelial cells (23, 24) . Co-immunostaining for PDI and GRO-α, a chemokine secreted from these small granules, showed partial co-localization of these proteins ( Figure 3C ). Similar partial colocalization of PDI with Monocyte Chemoattractant Protein-1 (MCP-1) was observed in HUVECs
(data not shown). MCP-1 has previously been shown to co-localize with GRO-α in small secretory granules (23, 24) .
PDI was also detected in tubulovescicular structures of the endoplasmic reticulum and in small granules close to the cell membrane by immunoelectron microscopy on ultrathin cryosections of HUVECs ( Figure 3D) . No PDI was observed in Weibel-Palade bodies. In agreement with the immunofluorescence data, immunogold labeling of PDI was observed in small, moderately electron dense granules of about 100-200 nm ( Figure 3E ). In addition, immunogold staining confirmed the association of PDI with the plasma membrane of activated endothelial cells ( Figure 3G ) while no plasma associated PDI was detected in resting cells ( Figure 3F ). 
PDI is released from cultured endothelial cells upon laser injury and is required for
calcium sensitive dye, Rhod-2, showed rapid calcium elevation (pseudo colored green) captured in a confocal intravital image ( Figure 4D ). This observation is akin to the spread of the calcium wave observed in cultured endothelial cells where laser activation of a single cell causes subsequent activation of surrounding cells. In addition, following laser injury and the calcium wave spreading over the endothelium in vivo, PDI antigen was detected at the site of laser injury using a non-inhibitory polyclonal affinity purified anti-PDI antibody labeled with Alexa 647 (18) . The PDI antigen post-laser injury was seen to spread around the circumference of the vessel wall whereas no PDI was detected prior to endothelial activation ( Figure 4D ).
PDI is released from endothelial cells upon cell injury in vivo:
PDI is expressed at the site of a developing thrombus in the laser injury model and platelets are one potential source of the PDI (18) . The presence of an alternative source of PDI at sites of laser injury was suggested by the kinetics of PDI appearance prior to platelet accumulation during thrombus formation and by the observation that fibrin generation was inhibited in the presence of a PDI-blocking antibody in PAR4-/-mice. In the latter experiment, fibrin generation, observed even in the absence of a significant platelet thrombus, is inhibited in the presence of inhibitory anti-PDI antibodies (18) .
The presence of PDI in plasma has been controversial (19, 20) . We examined both human and (18) . Purified anti-CD41 Fab fragments were used to visualize platelet thrombus formation (25) . Seven or eight thrombi were induced in a wild type mouse and PDI expression and platelet accumulation were quantified. Subsequently the mouse was treated with eptifibatide and additional thrombi induced to determine the effect of inhibition of platelet thrombus formation on PDI expression.
Representative images of platelet thrombus formation and PDI expression after laser-induced injury prior to (left panels) and after (right panels) eptifibatide infusion are shown in Figure 5A . figure S2) . In addition, with inhibition of cell activation by using a prostacyclin analog sodium beraprost in vivo, no PDI associated fluorescence was detected ( Figure 5D , curve 2), compared to untreated animals ( Figure 5D , curve 1). These data indicate that both endothelial cells and platelets contribute to PDI accumulation at sites of laser-induced thrombus formation. 
Discussion
We have determined that PDI is rapidly released from endothelial cells both in vitro and in vivo and contributes to initiation of fibrin formation on activated endothelial cells in contact with plasma as well as in our laser injury thrombosis model. PDI is detected at the site of vessel wall injury in vivo in the absence of any platelet accumulation. Normal fibrin generation is observed even in the presence of an inhibitor of platelet aggregation, suggesting that PDI released from endothelial cells is critical for thrombus formation after laser induced injury.
Since PDI antigen is not detected in plasma, any PDI observed at sites of laser injury in our thrombosis model is released from cells activated at the site. Catalytically active PDI can be released from activated platelets (19) . However, the kinetics of PDI accumulation at sites of laser injury in the presence and the absence of eptifibatide suggest that PDI observed shortly after generation of the laser-induced injury and before significant numbers of platelets accumulate is derived from endothelial cells. Platelets contribute to the more sustained PDI (11, 12) . However this mechanism of control of tissue factor activity remains controversial (13, 30, 31) . Alternatively PDI may regulate tissue factor activity by some mechanism unrelated to its oxido-reductive catalytic activity or PDI may regulate the pathway to thrombin generation through mechanisms unrelated to plateletassociated molecules or tissue factor. Activated platelets have generally been thought to provide the membrane surfaces on which the enzyme-cofactor complexes of blood coagulation assemble to support the catalytic reactions of these complexes. It is thus striking that we observe equivalent amounts of fibrin generated after laser-induced vessel wall injury in the presence or absence of a platelet thrombus. This result indicates that membrane surfaces other than those of the activated platelet may support thrombin generation resulting in fibrin deposition. These other membrane surfaces could include endothelial cells and/or other membranes at the site of thrombus formation that have phosphatidylserine on the outer membrane surface. Cell-derived microparticles that express phosphatidylserine on their surface have previously been shown to accumulate at sites of thrombus formation after laser induced injury (27, 31). Platelet microparticles derived in vitro have been reported to bear detectable amounts of PDI (19, 37).
Hence, it is possible that both vessel wall endothelial cells and cell microparticles provide two of the necessary components, PDI and the membrane surface, to support fibrin deposition.
In sum our data indicate that extracellular PDI accumulates at sites of laser injury and both endothelial cells and platelets contribute to the available PDI. Inhibition of PDI has a dramatic effect on platelet thrombus formation and fibrin deposition in our laser injury model of thrombosis. PDI may represent a novel target for antithrombotic intervention but the potential consequences of inhibition of extracellular PDI needs to be thoroughly evaluated in animal models to understand the possible risk-benefit ratio of such interventions. Median fluorescence is presented versus time after vessel wall injury.
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